Clinical Trials

  • We are inviting patients without autoimmune disorders to help us compare to rheumatoid arthritis patients with inflammation in soft tissues. With a combination of blood work, a full-body FDG PET-CT scan, questionnaires, and a soft tissue biopsy (from an area around the belly button), we hope to see how tissue inflammation interacts with these multiple areas of physiology. A second visit four months later would be the same, except for the FDG PET-CT scan - these visits typically take up to 5 hours to complete.
  • We are inviting patients with active Rheumatoid Arthritis (RA) to help us better understand how treatment options affect inflammation in soft tissues. With a combination of blood work, a full-body FDG PET-CT scan, questionnaires, and a soft tissue biopsy (from an area around the belly button), we hope to see how RA interacts with these multiple areas of physiology. A second visit four months later will be the same as the first visit - these visits typically take up to 6 hours to complete.
  • The purpose of this study is to develop a cohort of patients with early scleroderma and to collect data onclinical outcomes, radiological tests, laboratory tests, and to obtain biological specimens for testing.
  • This research is being done to determine how variations in genes may explain the different risk to develop scleroderma (or CREST) seen in African American patients compared to other populations. People who are African American with scleroderma (or CREST) may join. This research involves a blood draw and physical exams.
  • This is a 6-week randomized, double-blind trial of 4 different non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of pain score from baseline at 4 weeks to the change of pain score from baseline at 6 weeks. Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and exclusion criteria will be randomized into one of the four arms after an initial one week washout period, including: 1) indomethacin 75mg Q12H; 2) diclofenac 75mg Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H.
  • We are doing a research study to learn more about why people with rheumatoid arthritis (RA) are prone to heart disease. We are recruiting patients diagnosed with Rheumatoid Arthritis without a personal history of heart disease. This study involves one initial full visit as described below, and a brief follow up visit that will take place approximately 2 or more years later. We would incorporate questionnaires, fasting blood tests, 3D-Echocardiogram, PET-CT scan with a cardiac stress test. The 3D-Echocardiogram, blood tests, questionnaires, and a quick CT-scan would be done 3 years later.
  • We invite you to take part in this research study because you have Rheumatoid Arthritis (RA) or Systemic Lupus (SLE). Patients with RA & SLE develop severe heart disease and heart failure much more frequently than healthy people in a way that suggests some component of the immune response that results in rheumatoid arthritis and systemic lupus is responsible for the heart injury.
  • We are studying a medication to see if it is effective in reducing the disease activity of systemic lupus erythematosus (SLE), which is the most common form of lupus. You may qualify for the Achtar study if you have persistently active SLE, are 18 years of age or older, and: Have rash and/or arthritis as part of your SLE symptoms Are currently taking prednisone (or equivalent) as part of your SLE treatment. Additional requirements apply. If you qualify and agree to participate, the study treatment and study-related care will be provided to you at no cost.
  • The study aims to compare the effect two different RA treatments on cardiovascular health in patients who are considering a treatment change. The study is recruiting patients who are only taking methotrexate and are switching treatment due to a lack of improvement. The trial will randomize participants to take a TNF inhibitor (Enbrel or Humira) in addition to their methotrexate or to take Triple Therapy (methotrexate + sulfasalazine + hydroxychloroquine sulfate). The study will provide you with all trial medications (excluding methotrexate) for the 6-month duration of the study.